Trial Profile
A phase II study of MIQ-001 for the treatment of secondary progressive multiple sclerosis (SP-MS).
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 30 Mar 2016
Price :
$35
*
At a glance
- Drugs MIQ 001 (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- 30 Mar 2016 New trial record